The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma
Advanced Science · 2025-10 · 12 (37)
DOI: 10.1002/advs.202501774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 26.06.2025. Verfasst von Shuai Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Lipid Metabolism, GATA6 Transcription Factor, Pancreatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo para o Desenvolvimento das Ciências e da Tecnologia, National Natural Science Foundation of China, Universidade de Macau.
Abstract (Originalsprache)
Metabolic reprogramming is a hallmark of cancer, with dysregulated lipid metabolism contributing to tumor progression and therapy resistance. This study identifies the DNA demethylase TET3 as a key regulator of lipogenic metabolism in pancreatic ductal adenocarcinoma (PDAC). TET3 expression is elevated in the lipogenic PDAC subtype and correlates with poor patient prognosis. Genetic ablation of TET3 disrupts lipid homeostasis, alters the saturated‐to‐monounsaturated fatty acid ratio, and reduces proliferative capacity. Mechanistically, TET3 represses GATA6 expression through recruitment of histone deacetylases (HDACs) to its promoter, leading to H3K27 deacetylation, independent of its catalytic activity. Loss of TET3 derepresses GATA6 , which in turn suppresses lipogenic enzymes, such as stearoyl‐CoA desaturase ( SCD ) and acyl‐CoA synthetase long‐chain family member 3 ( ACSL3 ), and sensitizes cells to ferroptosis. Notably, combined treatment with the HDAC inhibitor SAHA and the ferroptosis inducer Erastin significantly enhances gemcitabine‐induced cytotoxicity in lipogenic PDAC cells. These findings uncover a previously unrecognized non‐catalytic function of TET3 in sustaining lipid metabolic reprogramming in PDAC. Targeting the TET3/GATA6 axis in combination with ferroptosis and epigenetic modulators offers a promising strategy to overcome therapeutic resistance in aggressive pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
- Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, 999078, China.
- Department of Biochemistry and Molecular Cell Biology & Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
ORCID-Profile: Jianxiu Yu, Ruiyu Xie
Förderung
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
- National Natural Science Foundation of China
- Universidade de Macau
Zitieren
APA
Liu, S., Kang, S., Lin, N., Zhang, W., Wang, S., Ren, Y., Ding, X., Yu, J., & Xie, R. (2025). The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma. Advanced Science, 12(37). https://doi.org/10.1002/advs.202501774
Vancouver
Liu S, Kang S, Lin N, Zhang W, Wang S, Ren Y, et al. The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma. Advanced Science. 2025;12(37). doi:10.1002/advs.202501774
BibTeX
@article{Liu2025,
author = {Liu, Shuai and Kang, Shaobo and Lin, Na and Zhang, Wenqi and Wang, Shiwen and Ren, Yuqing and Ding, Xiaofan and Yu, Jianxiu and Xie, Ruiyu},
title = {The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {37},
doi = {10.1002/advs.202501774}
}
EUVIMED